Lilly Zyprexa, Symbyax Labeling Strengthened
This article was originally published in The Pink Sheet Daily
Executive Summary
Update elevates information on weight gain and hyperlipidemia from adverse event precaution to “Warning” status and adds to elevated blood sugar warning.
You may also be interested in...
Lilly’s Zyprexa Gets MedGuide, Labeling Update And New Indication
Antipsychotic clears FDA for treatment-resistant depression in combination with fluoxetine, as does combo pill Symbyax.
Lilly’s Zyprexa Gets MedGuide, Labeling Update And New Indication
Antipsychotic clears FDA for treatment-resistant depression in combination with fluoxetine, as does combo pill Symbyax.
Comparative Research Needs New Approach To Answer Real-Life Questions
To get the most out of the new funding for research on the comparative effectiveness of health care products and services, research needs to go in new directions so that it can answer real-world questions, two former CMS officials said at a recent forum at the American Enterprise Institute